Glioblastoma Multiforme Treatment Market Share, Growth, Trends and Investment Opportunities

Glioblastoma Multiforme Treatment Market Size- By Drug Class, By Treatment, By End Use - Regional Outlook, Competitive Strategies and Segment Forecasts to 2032

Glioblastoma Multiforme Treatment Market Size- By Drug Class, By Treatment, By End Use - Regional Outlook, Competitive Strategies and Segment Forecasts to 2032

Published: Dec 2022 Report ID: HLCA2229 Pages: 1 - 225 Formats*:     
Category : Healthcare
Global Glioblastoma Multiforme Treatment Market Overview:

According to SPER Market Research, the Global Glioblastoma Multiforme Treatment Market is estimated to reach USD 6.05 billion by 2032 with a CAGR of 9.04%.

Glioblastoma multiforme (GBM) is an astrocytic-differentiated malignant tumour classified by the WHO as grade IV. The description and development of theories about these tumours have been covered in a wide range of historical records since they are among the most frequently clinically diagnosed central nervous system (CNS) oncological entry.The market is anticipated to grow as a result of a number of factors, including increased R&D, favourable regulatory settings, and the rising occurrence of glioblastoma multiforme. A strong pipeline is likely to significantly influence the glioblastoma multiforme (GBM) therapeutic market during the projected timeframe. It is estimated that the occurrence of brain tumours will drive market expansion throughout the course of the anticipated timeframe.The market is predicted to be boosted in the coming years by the growing acceptance of novel medicines and combination therapies. The need for a personalised treatment strategy to handle glioblastoma multiforme is anticipated to rise as a result of tumour heterogeneity and variance in patient-to-patient treatment approaches. The approval of new therapies is anticipated to lengthen the life expectancy of glioblastoma multiforme patients. 

Impact of COVID-19 on the Global Glioblastoma Multiforme Treatment Market
The market for glioblastoma treatments has suffered as a result of COVID-19. During the COVID-19 pandemic, many ICU resources, including ventilators, personal protective equipment, and medical personnel, were diverted to COVID-19 cases, leading to the cessation of surgical neuro-oncology treatments. During the pandemic, there was instability in the ability to provide essential cancer patients with effective medical care. Additionally, it appears that individuals with glioblastoma are more susceptible to the COVID-19 infection, which led to the cancellation of surgeries and therapies. The worldwide glioma treatment market consequently has a significant impact on the market.  



Scope of the Report:
 Report Metric Details
 Market size available for years 2019-2032
 Base year considered 2021
 Forecast period 2022-2032
 Segments coveredBy Drug Class, By Treatment, By End Use
 Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa
 Companies CoveredAmgen, Inc., Amneal Pharmaceuticals, Arbor Pharmaceuticals, LLC, F. Hoffmann-La Roche Ltd., Karyopharm Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd
Global Glioblastoma Multiforme Treatment Market Segmentation:

By Drug Class: Based on the Drug Class, Global Glioblastoma Multiforme Treatment Market is segmented as; Bevacizumab, Carmustine Wafers, Lomustine, Temozolomide, Others.

By Treatment: Based on the Treatment, Global Glioblastoma Multiforme Treatment Market is segmented as; Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy, Tumor Treating Field (TTF) Therapy.

By End Use: 
Based on the End Use, Global Glioblastoma Multiforme Treatment Market is segmented as; Ambulatory Surgical Centres, Clinics, Hospitals.

By Region: North America accounted for the largest percentage in recent years. Government support for the expansion of the healthcare sector, together with increased awareness of unusual ailments, simple access to top-notch medical facilities, and kind reimbursement policies, are some of the key factors driving regional market growth. Asia Pacific is anticipated to grow at the fastest rate throughout the projection period due to a number of factors, including the introduction of temozolomide generics, an improved economy, an increase in the world's elderly population, and rising healthcare investment.
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges 
4.2. COVID-19 Impacts of the Global Glioblastoma Multiforme Treatment Market 

5. Market variables and outlook
5.1. SWOT analysis 
5.1.1 Strengths 
5.1.2 Weaknesses 
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis 
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape 
5.2.4 Technological landscape 
5.2.5 Environmental landscape 
5.2.6 Legal landscape 
5.3. PORTER’S five forces analysis 
5.3.1 Bargaining power of suppliers 
5.3.2 Bargaining power of Buyers 
5.3.3 Threat of Substitute 
5.3.4 Threat of new entrant 
5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global Glioblastoma Multiforme Treatment Market, By Drug Class, 2019-2032 (USD Million)
6.1. Bevacizumab
6.2. Carmustine Wafers
6.3. Lomustine
6.4. Temozolomide
6.5. Others

7. Global Glioblastoma Multiforme Treatment Market, By Treatment, 2019-2032 (USD Million)
7.1. Chemotherapy
7.2. Immunotherapy
7.3. Radiation Therapy
7.4. Surgery
7.5. Targeted Therapy
7.6. Tumor Treating Field (TTF) Therapy

8. Global Glioblastoma Multiforme Treatment Market, By End Use, 2019-2032 (USD Million)
8.1. Ambulatory Surgical Centers
8.2. Clinics
8.3. Hospitals

9. Global Glioblastoma Multiforme Treatment Market, By Region, 2019-2032 (USD Million)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia 
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa

10. Company Profiles
10.1. Amgen, Inc.
10.1.1. Company details 
10.1.2. Financial outlook
10.1.3. Product summary 
10.1.4. Recent developments

10.2. Amneal Pharmaceuticals
10.2.1. Company details 
10.2.2. Financial outlook
10.2.3. Product summary 
10.2.4. Recent developments

10.3. Arbor Pharmaceuticals, LLC
10.3.1. Company details 
10.3.2. Financial outlook
10.3.3. Product summary 
10.3.4. Recent developments

10.4. F. Hoffmann-La Roche
10.4.1. Company details 
10.4.2. Financial outlook
10.4.3. Product summary 
10.4.4. Recent developments

10.5. Karyopharm Therapeutics, Inc.
10.5.1. Company details 
10.5.2. Financial outlook
10.5.3. Product summary 
10.5.4. Recent developments

10.6. Merck & Co., Inc.
10.6.1. Company details 
10.6.2. Financial outlook
10.6.3. Product summary 
10.6.4. Recent developments

10.7. Pfizer Inc.
10.7.1. Company details 
10.7.2. Financial outlook
10.7.3. Product summary 
10.7.4. Recent developments

10.8. Sumitomo Dainippon Pharma Oncology Inc. (Boston Biomedical Inc.)
10.8.1. Company details 
10.8.2. Financial outlook
10.8.3. Product summary 
10.8.4. Recent developments

10.9. Sun Pharmaceutical Industries Ltd.
10.9.1. Company details 
10.9.2. Financial outlook
10.9.3. Product summary 
10.9.4. Recent developments

10.10. Teva Pharmaceutical Industries Ltd.
10.10.1. Company details 
10.10.2. Financial outlook
10.10.3. Product summary 
10.10.4. Recent developments

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3


Frequently Asked Questions About This Report
The Glioblastoma Multiforme Treatment Market is projected to reach USD 6.05 billion by 2032, growing at a CAGR of 9.04% during the forecast period.
The Glioblastoma Multiforme Treatment Market grew in market size from 2021. The Market is expected to reach USD 6.05 billion by 2032, at a CAGR of 9.04% during the forecast period.
The Glioblastoma Multiforme Treatment Market CAGR of 9.04% during the forecast period.
The Glioblastoma Multiforme Treatment Market size is USD 9.04 billion from 2022 to 2032.
The Glioblastoma Multiforme Treatment Market segment is Covered By Drug Class, By Treatment, By End Use.
The North America and Europe region is anticipated to have the highest market share in the Glioblastoma Multiforme Treatment Market.
The key players in the market include Companies Covered Amgen, Inc., Amneal Pharmaceuticals, Arbor Pharmaceuticals, LLC, F. Hoffmann-La Roche Ltd., Karyopharm Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.
The market is predicted to be boosted in the coming years by the growing acceptance of novel medicines and combination therapies. The need for a personalised treatment strategy to handle glioblastoma multiforme is anticipated to rise as a result of tumour heterogeneity and variance in patient-to-patient treatment approaches.
Not able to find what you are looking for? Need customization in the existing report?
Click Here
PLACE AN ORDER
  • 15% off
     
    $ 4250
  • 20% off
             
    $ 5650
  • 25% off
         
    $ 7450
Pre-Purchase Inquiry
SEND AN INQUIRY
NEED CUSTOMIZATION?
Request Customization
CALL OR EMAIL US
US:
India:
Email:
100% Secure Payment

SPER American Express
SPER VISA
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join Our SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB

SPER

Market Research

We are the leading, full-service global market research and consulting company.

Certificates
iso-1 iso-1
Secure Payments
SPER Payment Options
Connect with us